Float Short %

10.76

Margin Of Safety %

Put/Call OI Ratio

0.47

EPS Next Q Diff

-0.19

EPS Last/This Y

1.33

EPS This/Next Y

1.08

Price

8.13

Target Price

29.83

Analyst Recom

1.42

Performance Q

-27.64

Upside

-1,600.6%

Beta

1.1

Ticker: RGNX

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	RGNX	13.79	0.42	3.26	5794
2026-01-26	RGNX	13.87	0.69	0.36	7260
2026-01-27	RGNX	13.43	0.59	0.47	8836
2026-01-28	RGNX	11.01	0.57	1.47	9877
2026-01-29	RGNX	11.6	0.77	0.64	11410
2026-01-30	RGNX	11.16	0.73	4.79	12195
2026-02-02	RGNX	10.76	0.87	6.06	13378
2026-02-03	RGNX	10.87	0.92	0.70	13978
2026-02-04	RGNX	10.77	0.92	0.73	14331
2026-02-05	RGNX	10.28	0.88	0.48	15725
2026-02-06	RGNX	10.32	0.83	0.85	16467
2026-02-09	RGNX	10.3	0.80	6.52	17726
2026-02-10	RGNX	8.84	0.89	1.74	18554
2026-02-11	RGNX	8.48	0.61	2.05	19196
2026-02-12	RGNX	8.34	0.55	2.42	19143
2026-02-13	RGNX	7.98	0.54	0.34	19098
2026-02-17	RGNX	8.03	0.50	0.38	19276
2026-02-18	RGNX	7.89	0.49	0.11	18995
2026-02-19	RGNX	8.41	0.47	3.61	19428
2026-02-20	RGNX	8.13	0.47	0.14	19542
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	RGNX	13.79	22.6	222.9	-3.26
2026-01-26	RGNX	13.85	22.6	243.0	-3.26
2026-01-27	RGNX	13.42	22.6	237.7	-3.26
2026-01-28	RGNX	11.03	22.6	215.6	-3.26
2026-01-29	RGNX	11.61	22.6	251.3	-3.26
2026-01-30	RGNX	11.15	22.6	236.1	-3.26
2026-02-02	RGNX	10.76	22.6	236.6	-3.26
2026-02-03	RGNX	10.85	22.6	243.3	-3.26
2026-02-04	RGNX	10.77	22.6	-	-3.26
2026-02-05	RGNX	10.29	22.6	-	-3.26
2026-02-06	RGNX	10.32	22.6	-	-3.26
2026-02-09	RGNX	10.30	22.6	-	-3.26
2026-02-10	RGNX	8.84	22.6	-	-3.26
2026-02-11	RGNX	8.49	22.6	-	-3.26
2026-02-12	RGNX	8.35	22.6	-	-3.26
2026-02-13	RGNX	7.99	16.9	-	-3.26
2026-02-17	RGNX	8.03	16.9	-	-3.26
2026-02-18	RGNX	7.89	16.9	-	-3.26
2026-02-19	RGNX	8.41	16.9	-	-3.26
2026-02-20	RGNX	8.13	16.9	-	-3.26
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	RGNX	-0.71	-0.65	10.90
2026-01-26	RGNX	-0.71	-0.04	10.90
2026-01-27	RGNX	-0.71	-0.04	10.90
2026-01-28	RGNX	-0.71	-0.04	11.24
2026-01-29	RGNX	-0.71	-0.04	11.24
2026-01-30	RGNX	-0.71	-0.04	11.24
2026-02-02	RGNX	-0.71	-0.08	11.24
2026-02-03	RGNX	-0.71	-0.08	11.24
2026-02-04	RGNX	-0.71	-0.08	11.24
2026-02-05	RGNX	-0.71	-0.08	11.24
2026-02-06	RGNX	-0.71	-0.08	11.24
2026-02-09	RGNX	-0.71	0.07	11.24
2026-02-10	RGNX	-0.71	0.07	11.24
2026-02-11	RGNX	-0.71	0.07	10.70
2026-02-12	RGNX	-0.71	0.07	10.70
2026-02-13	RGNX	-0.71	0.07	10.70
2026-02-17	RGNX	-0.71	3.00	10.76
2026-02-18	RGNX	-0.68	3.00	10.76
2026-02-19	RGNX	-0.68	3.00	10.76
2026-02-20	RGNX	-0.68	3.00	10.76
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.2

Avg. EPS Est. Current Quarter

-0.8

Avg. EPS Est. Next Quarter

-1.39

Insider Transactions

-0.68

Institutional Transactions

Beta

1.1

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

82.5

Max Drawdown 5-Year %

-88.4

Target Price

29.83

P/E

Forward P/E

PEG

P/S

2.55

P/B

2.55

P/Free Cash Flow

EPS

-3.49

Average EPS Est. Cur. Y

-3.26

EPS Next Y. (Est.)

-2.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-110.29

Relative Volume

1.13

Return on Equity vs Sector %

-139.2

Return on Equity vs Industry %

-121.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.06

EBIT Estimation

REGENXBIO Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 353

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today

news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance

stock history RGNX – REGENXBIO Inc. invest stock market

stock prices RGNX premarket after hours

ticker RGNX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RGNX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y